Predictors of Progression-Free Survival and Local Tumor Control after Percutaneous Thermal Ablation of Oligometastatic Breast Cancer: Retrospective Study
To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS). A total of 33 women (mean age 52 ± 12 years old; range, 28-69 years), underwent 46 thermal ablations of liver (n = 3...
Uloženo v:
| Vydáno v: | Journal of vascular and interventional radiology Ročník 31; číslo 8; s. 1201 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.08.2020
|
| Témata: | |
| ISSN: | 1535-7732, 1535-7732 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS).
A total of 33 women (mean age 52 ± 12 years old; range, 28-69 years), underwent 46 thermal ablations of liver (n = 35), lung (n = 7), and bone/soft tissue (n = 4) metastases. Mean tumor diameter was 18 ± 15 mm (range, 6-50 mm). Ablations were performed to eradicate all evident sites of disease (n = 24) or to control growing sites in the setting of other stable or responding sites of disease (n = 22). Patient characteristics, ablation margins, imaging responses, and cases of PFS were assessed. Follow-up imaging was performed using contrast-enhanced computed tomography (CT), magnetic resonance (MR) imaging, or positron-emission tomography/ CT.
Median PFS was 10 months (95% confidence interval [CI], 6.2 -14.5 months), and time to local progression was 11 months (95% CI, 5-16 months). Eight patients (24%) maintained no evidence of disease during a median follow-up period of 39 months. Ablation margin ≥5 mm was associated with no local tumor progression. Longer PFS was noted in estrogen receptor-positive patients (12 vs 4 months; P = .037) and younger patients (12 vs 4 months; P = .039) treated to eradicate all sites of disease (13 vs 5 months; P = .05). Eighteen patients (55%) developed new metastases during study follow-up.
Thermal ablation of oligometastatic pulmonary, hepatic, bone, and soft tissue tumors can eliminate local tumor progression if margins are ≥5 mm. Longer PFS was observed in patients who were estrogen receptor-positive and patients who were younger and in whom all sites of disease were eradicated. |
|---|---|
| AbstractList | To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS).PURPOSETo describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS).A total of 33 women (mean age 52 ± 12 years old; range, 28-69 years), underwent 46 thermal ablations of liver (n = 35), lung (n = 7), and bone/soft tissue (n = 4) metastases. Mean tumor diameter was 18 ± 15 mm (range, 6-50 mm). Ablations were performed to eradicate all evident sites of disease (n = 24) or to control growing sites in the setting of other stable or responding sites of disease (n = 22). Patient characteristics, ablation margins, imaging responses, and cases of PFS were assessed. Follow-up imaging was performed using contrast-enhanced computed tomography (CT), magnetic resonance (MR) imaging, or positron-emission tomography/ CT.MATERIALS AND METHODSA total of 33 women (mean age 52 ± 12 years old; range, 28-69 years), underwent 46 thermal ablations of liver (n = 35), lung (n = 7), and bone/soft tissue (n = 4) metastases. Mean tumor diameter was 18 ± 15 mm (range, 6-50 mm). Ablations were performed to eradicate all evident sites of disease (n = 24) or to control growing sites in the setting of other stable or responding sites of disease (n = 22). Patient characteristics, ablation margins, imaging responses, and cases of PFS were assessed. Follow-up imaging was performed using contrast-enhanced computed tomography (CT), magnetic resonance (MR) imaging, or positron-emission tomography/ CT.Median PFS was 10 months (95% confidence interval [CI], 6.2 -14.5 months), and time to local progression was 11 months (95% CI, 5-16 months). Eight patients (24%) maintained no evidence of disease during a median follow-up period of 39 months. Ablation margin ≥5 mm was associated with no local tumor progression. Longer PFS was noted in estrogen receptor-positive patients (12 vs 4 months; P = .037) and younger patients (12 vs 4 months; P = .039) treated to eradicate all sites of disease (13 vs 5 months; P = .05). Eighteen patients (55%) developed new metastases during study follow-up.RESULTSMedian PFS was 10 months (95% confidence interval [CI], 6.2 -14.5 months), and time to local progression was 11 months (95% CI, 5-16 months). Eight patients (24%) maintained no evidence of disease during a median follow-up period of 39 months. Ablation margin ≥5 mm was associated with no local tumor progression. Longer PFS was noted in estrogen receptor-positive patients (12 vs 4 months; P = .037) and younger patients (12 vs 4 months; P = .039) treated to eradicate all sites of disease (13 vs 5 months; P = .05). Eighteen patients (55%) developed new metastases during study follow-up.Thermal ablation of oligometastatic pulmonary, hepatic, bone, and soft tissue tumors can eliminate local tumor progression if margins are ≥5 mm. Longer PFS was observed in patients who were estrogen receptor-positive and patients who were younger and in whom all sites of disease were eradicated.CONCLUSIONSThermal ablation of oligometastatic pulmonary, hepatic, bone, and soft tissue tumors can eliminate local tumor progression if margins are ≥5 mm. Longer PFS was observed in patients who were estrogen receptor-positive and patients who were younger and in whom all sites of disease were eradicated. To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS). A total of 33 women (mean age 52 ± 12 years old; range, 28-69 years), underwent 46 thermal ablations of liver (n = 35), lung (n = 7), and bone/soft tissue (n = 4) metastases. Mean tumor diameter was 18 ± 15 mm (range, 6-50 mm). Ablations were performed to eradicate all evident sites of disease (n = 24) or to control growing sites in the setting of other stable or responding sites of disease (n = 22). Patient characteristics, ablation margins, imaging responses, and cases of PFS were assessed. Follow-up imaging was performed using contrast-enhanced computed tomography (CT), magnetic resonance (MR) imaging, or positron-emission tomography/ CT. Median PFS was 10 months (95% confidence interval [CI], 6.2 -14.5 months), and time to local progression was 11 months (95% CI, 5-16 months). Eight patients (24%) maintained no evidence of disease during a median follow-up period of 39 months. Ablation margin ≥5 mm was associated with no local tumor progression. Longer PFS was noted in estrogen receptor-positive patients (12 vs 4 months; P = .037) and younger patients (12 vs 4 months; P = .039) treated to eradicate all sites of disease (13 vs 5 months; P = .05). Eighteen patients (55%) developed new metastases during study follow-up. Thermal ablation of oligometastatic pulmonary, hepatic, bone, and soft tissue tumors can eliminate local tumor progression if margins are ≥5 mm. Longer PFS was observed in patients who were estrogen receptor-positive and patients who were younger and in whom all sites of disease were eradicated. |
| Author | Solomon, Stephen B Ridouani, Fourat Deipolyi, Amy R Bromberg, Jacqueline F Sofocleous, Constantinos T Bryce, Yolanda |
| Author_xml | – sequence: 1 givenname: Fourat surname: Ridouani fullname: Ridouani, Fourat organization: Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 2 givenname: Stephen B surname: Solomon fullname: Solomon, Stephen B organization: Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 3 givenname: Yolanda surname: Bryce fullname: Bryce, Yolanda organization: Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 4 givenname: Jacqueline F surname: Bromberg fullname: Bromberg, Jacqueline F organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 5 givenname: Constantinos T surname: Sofocleous fullname: Sofocleous, Constantinos T organization: Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 6 givenname: Amy R surname: Deipolyi fullname: Deipolyi, Amy R email: deipolya@mskcc.org organization: Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: deipolya@mskcc.org |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32698956$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEFLxDAQhYMo6qp_wIPk6KU1SZt0600XV4WFXXQ9lzSdape2WSdpYX-K_9aIK8gc5vF4fMObCTnsbQ-EXHIWc8bVzSbejA3GggkWMxEH64CccpnIKMsScfhPn5CJcxvG2DTMMTlJhMqnuVSn5GuFUDXGW3TU1nSF9h3Bucb20RwB6OuAYzPqluq-ogtrgloPnUU6s71HG_zaA9IVoBm87sEOjq4_ALsQvCtb7QPpB7xsm3fbgdfOB8_Qe4Qg6Uz3BvCWvkCAuS0Y34zhqB-q3Tk5qnXr4GK_z8jb_GE9e4oWy8fn2d0iMinLfAQ640qXVVKVaaZzIxNjgBut8jrLuTCCSa2TKhW5AimnJVd1DqKcylKJFNJMnJHrX-4W7ecAzhdd4wy07W-bQqRCyUTxTITo1T46lB1UxRabTuOu-Hun-Ab0qX28 |
| CitedBy_id | crossref_primary_10_1259_bjr_20211350 crossref_primary_10_1111_1754_9485_13594 crossref_primary_10_1080_02656736_2023_2290924 crossref_primary_10_1055_s_0040_1720949 crossref_primary_10_1259_bjr_20220434 crossref_primary_10_5306_wjco_v12_i9_725 crossref_primary_10_1007_s00330_025_11973_8 crossref_primary_10_1155_2021_3392433 crossref_primary_10_1155_2022_7839041 crossref_primary_10_1016_j_jvir_2022_03_016 crossref_primary_10_1016_j_ejro_2022_100430 crossref_primary_10_1055_s_0044_1786730 crossref_primary_10_1136_bcr_2023_256256 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 SIR. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2020 SIR. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.jvir.2020.02.016 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1535-7732 |
| ExternalDocumentID | 32698956 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- --K .1- .FO 08G 08P 0R~ 1B1 1P~ 1RT 354 4.4 457 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF AAEDT AAEDW AAKAS AALRI AAQQT AAQXK AAWTL AAXUO ABFRF ABLJU ABMAC ABWVN ACGFO ACRPL ADBBV ADBIZ ADMUD ADNMO ADZCM AEFWE AENEX AEVXI AFCTW AFJKZ AFRHN AFTJW AFTRI AFUWQ AHHHB AHRYX AITUG AIZYK AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BELOY CGR CS3 CUY CVF DU5 EBS ECM EFJIC EIF EJD EX3 F5P FDB FEDTE FGOYB G-2 GBLVA H0~ HEI HEK HMK HMO HVGLF HZ~ IHE JF9 JG8 KMI M28 M41 NPM NTWIH O9- OAG OAH OI~ OL1 OLY OLZ OU0 OVD OWU OWV OWW OWX OWY OWZ P2P R2- RIG ROL RPZ SAE SEL SES T8P TEORI UNMZH VVN WOQ WOW WUQ XH2 XXN XYM YQY Z5R ZGI 7X8 AIGII EFKBS |
| ID | FETCH-LOGICAL-c407t-ea716abd3db47a9c53cce1ca69f7912c205aa3d4296e558b16f9e2b85b624e472 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 17 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000556565100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1535-7732 |
| IngestDate | Thu Oct 02 11:36:36 EDT 2025 Thu Apr 03 07:06:29 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | Copyright © 2020 SIR. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c407t-ea716abd3db47a9c53cce1ca69f7912c205aa3d4296e558b16f9e2b85b624e472 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 32698956 |
| PQID | 2426536172 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2426536172 pubmed_primary_32698956 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-Aug 20200801 |
| PublicationDateYYYYMMDD | 2020-08-01 |
| PublicationDate_xml | – month: 08 year: 2020 text: 2020-Aug |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of vascular and interventional radiology |
| PublicationTitleAlternate | J Vasc Interv Radiol |
| PublicationYear | 2020 |
| SSID | ssj0008080 |
| Score | 2.3978462 |
| Snippet | To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1201 |
| SubjectTerms | Adult Aged Bone Neoplasms - diagnostic imaging Bone Neoplasms - mortality Bone Neoplasms - secondary Bone Neoplasms - surgery Breast Neoplasms - mortality Breast Neoplasms - pathology Cryosurgery - adverse effects Cryosurgery - mortality Databases, Factual Disease Progression Feasibility Studies Female Humans Liver Neoplasms - diagnostic imaging Liver Neoplasms - mortality Liver Neoplasms - secondary Liver Neoplasms - surgery Lung Neoplasms - diagnostic imaging Lung Neoplasms - mortality Lung Neoplasms - secondary Lung Neoplasms - surgery Margins of Excision Metastasectomy - adverse effects Metastasectomy - methods Metastasectomy - mortality Middle Aged Progression-Free Survival Radiofrequency Ablation - adverse effects Radiofrequency Ablation - mortality Retrospective Studies Risk Factors Soft Tissue Neoplasms - diagnostic imaging Soft Tissue Neoplasms - mortality Soft Tissue Neoplasms - secondary Soft Tissue Neoplasms - surgery Time Factors Tumor Burden |
| Title | Predictors of Progression-Free Survival and Local Tumor Control after Percutaneous Thermal Ablation of Oligometastatic Breast Cancer: Retrospective Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32698956 https://www.proquest.com/docview/2426536172 |
| Volume | 31 |
| WOSCitedRecordID | wos000556565100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELVaQBUX2vJNKTISV6txEic2F0RXrDjANgIq7W3lOGO0iN1AdheJn8K_7UycFadKlXqJcsmX_TIztp_fY-wkNR6M1lZoMKnAKCmF8SYTMndGAYDzzrdmE_lgoIdDU3QTbrOOVrmMiW2grmpHc-Q_KJWohPLt2dOzINcoWl3tLDQ-stUESxmidOXDd7Vw0kwMeqkKq8gk7jbNBH7Xw8uY9EDjqNXslNnfS8w21fQ__-9LfmEbXZHJzwMqvrIPMN1kn667ZfQt9lY0dE5GO7z2vCCOVtDnEP0GgN8uMIAgBLmdVvyKsh2_W0zqhvcCsZ23zuK8gMYtsLiEejHjiDeM8fjQMrDr6Ma_Hsf39QTmlrYtjR3_SQz4Oe8R0ppTfgN4s-VWT06Mxtdt9rt_cde7FJ1Hg3A4FJwLsDjgsmWVVGWaW-NU4hxIZzPjcyNjF0fK2qTCrJeBUrqUmTcQl1qVWZxCmsc7bGVaT2GPceym1v9aauvTKrE6QqykkQUro8pItc-Ol40-wn-AFjbCF47em32f7YaeGz0FsY4RlqdG4yDw4B-u_sbWCRCB33fIVj1GAPjO1tzLfDxrjlpw4XFQXP8B8wzczg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictors+of+Progression-Free+Survival+and+Local+Tumor+Control+after+Percutaneous+Thermal+Ablation+of+Oligometastatic+Breast+Cancer%3A+Retrospective+Study&rft.jtitle=Journal+of+vascular+and+interventional+radiology&rft.au=Ridouani%2C+Fourat&rft.au=Solomon%2C+Stephen+B&rft.au=Bryce%2C+Yolanda&rft.au=Bromberg%2C+Jacqueline+F&rft.date=2020-08-01&rft.eissn=1535-7732&rft.volume=31&rft.issue=8&rft.spage=1201&rft_id=info:doi/10.1016%2Fj.jvir.2020.02.016&rft_id=info%3Apmid%2F32698956&rft_id=info%3Apmid%2F32698956&rft.externalDocID=32698956 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-7732&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-7732&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-7732&client=summon |